Retatrutide Peptide for sale.
In the evolving field of metabolic study, Retatrutide peptide (also known as LY3437943 or reta-peptide) represents a significant breakthrough as a first-in-class triple hormone receptor agonist. While previous generations of research peptides focused on single or dual receptor pathways, Retatrutide is engineered to simultaneously target the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. At Polaris Peptides, we provide researchers with the high-purity materials necessary to explore how this “tri-agonist” approach influences energy expenditure and nutrient metabolism.
The Science of Triple Receptor Agonism
The Retatrutide peptide is a 39-amino-acid synthetic chain. Its unique architecture allows for a coordinated metabolic response that is frequently studied for its potential to surpass the efficacy of dual agonists like Tirzepatide.
-
GIP Receptor: Enhances insulin secretion and may modulate lipid metabolism.
-
GLP-1 Receptor: Investigated for its role in slowing gastric emptying and suppressing appetite signals in the brain.
-
Glucagon Receptor: Studied for its ability to increase energy expenditure and stimulate thermogenesis, potentially balancing the glycemic effects of the other two pathways
Quantitative Research Options at Polaris PeptidesTo accommodate diverse experimental protocols—from micro-dosing to chronic high-volume studies—Polaris Peptides offers Retatrutide in several precisely measured lyophilized concentrations.Baseline and Pilot Study Vials: 5mg and 12mgThese concentrations are ideal for establishing initial dose-response curves and conducting short-term metabolic assays.Retatrutide 5mg: A precise option for small-scale in vitro assays or initial titration phases in animal models.Retatrutide 12mg: Frequently utilized in dose-escalation research to determine the threshold for maximum triple-receptor engagement.Specialized and Chronic Research Vials: 15mg, 24mg, and 35mgFor long-term longitudinal studies and high-throughput laboratory environments, our larger vials ensure batch-to-batch consistency across extended timelines.Retatrutide 15mg: An optimized intermediate dose for comparative studies against dual-agonist peptides.Retatrutide 24mg: Designed for multi-subject cohorts, providing a stable supply for continuous administration over several weeks.Retatrutide 35mg: Our highest-capacity vial, the Retatrutide 35mg option, is engineered for large-scale preclinical trials. This concentration minimizes variables associated with frequent reconstitution and helps maintain a steady-state hormonal profile in large research populations.Polaris Peptides Purity & Stability StandardsThe integrity of your research data depends on the chemical fidelity of your materials. Every batch of Retatrutide peptide from Polaris Peptides undergoes strict quality control:Analytical Purity: Verified at $\geq 99\%$ purity via High-Performance Liquid Chromatography (HPLC).Mass Spectrometry: Each vial is tested to ensure a molecular weight of approximately 4731.33 Da.Preservation: Provided as a sterile-filtered lyophilized powder. Store at $-20$°C for long-term stability.Important Handling and ReconstitutionRetatrutide should be reconstituted with bacteriostatic water or sterile saline under aseptic laboratory conditions. Once in solution, it is highly sensitive to temperature and should be stored at $4$°C for immediate use or aliquoted and frozen to prevent degradation from multiple freeze-thaw cycles.Strictly for Research and Laboratory UseAll products, including Retatrutide 5mg, 12mg, 15mg, 24mg, and 35mg, are intended STRICTLY for research and laboratory use only. These materials are not approved for human or animal consumption and are not intended for medical, diagnostic, or therapeutic applications.Contact for DocumentationFor batch-specific HPLC reports, Mass Spec data, or a Certificate of Analysis (COA), please email our team at sales@polaris-peptide.com.Polaris Peptides 302 S Jones Blvd, Suite 3020Las Vegas, NV 89107